These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 26135113)

  • 1. TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET.
    den Hollander MW; Bensch F; Glaudemans AW; Oude Munnink TH; Enting RH; den Dunnen WF; Heesters MA; Kruyt FA; Lub-de Hooge MN; Cees de Groot J; Pearlberg J; Gietema JA; de Vries EG; Walenkamp AM
    J Nucl Med; 2015 Sep; 56(9):1310-4. PubMed ID: 26135113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET with the 89Zr-labeled transforming growth factor-β antibody fresolimumab in tumor models.
    Oude Munnink TH; Arjaans ME; Timmer-Bosscha H; Schröder CP; Hesselink JW; Vedelaar SR; Walenkamp AM; Reiss M; Gregory RC; Lub-de Hooge MN; de Vries EG
    J Nucl Med; 2011 Dec; 52(12):2001-8. PubMed ID: 22072706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?
    Pöpperl G; Kreth FW; Herms J; Koch W; Mehrkens JH; Gildehaus FJ; Kretzschmar HA; Tonn JC; Tatsch K
    J Nucl Med; 2006 Mar; 47(3):393-403. PubMed ID: 16513607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas.
    Fueger BJ; Czernin J; Cloughesy T; Silverman DH; Geist CL; Walter MA; Schiepers C; Nghiemphu P; Lai A; Phelps ME; Chen W
    J Nucl Med; 2010 Oct; 51(10):1532-8. PubMed ID: 20847166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Drug Imaging:
    Jansen MH; Veldhuijzen van Zanten SEM; van Vuurden DG; Huisman MC; Vugts DJ; Hoekstra OS; van Dongen GA; Kaspers GL
    J Nucl Med; 2017 May; 58(5):711-716. PubMed ID: 27765855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. O-(2-[(18)F]fluoroethyl)-L-tyrosine uptake is an independent prognostic determinant in patients with glioma referred for radiation therapy.
    Sweeney R; Polat B; Samnick S; Reiners C; Flentje M; Verburg FA
    Ann Nucl Med; 2014 Feb; 28(2):154-62. PubMed ID: 24272067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
    Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
    J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-grade glioma radiation therapy target volumes and patterns of failure obtained from magnetic resonance imaging and 18F-FDOPA positron emission tomography delineations from multiple observers.
    Kosztyla R; Chan EK; Hsu F; Wilson D; Ma R; Cheung A; Zhang S; Moiseenko V; Benard F; Nichol A
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1100-6. PubMed ID: 24161427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
    Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 89Zr-Bevacizumab PET Visualizes Disease Manifestations in Patients with von Hippel-Lindau Disease.
    Oosting SF; van Asselt SJ; Brouwers AH; Bongaerts AH; Steinberg JD; de Jong JR; Lub-de Hooge MN; van der Horst-Schrivers AN; Walenkamp AM; Hoving EW; Sluiter WJ; Zonnenberg BA; de Vries EG; Links TP
    J Nucl Med; 2016 Aug; 57(8):1244-50. PubMed ID: 27173161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with
    Matsuda M; Ishikawa E; Yamamoto T; Hatano K; Joraku A; Iizumi Y; Masuda Y; Nishiyama H; Matsumura A
    J Neurooncol; 2018 Jul; 138(3):581-589. PubMed ID: 29524126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
    Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
    J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30.
    Perk LR; Stigter-van Walsum M; Visser GW; Kloet RW; Vosjan MJ; Leemans CR; Giaccone G; Albano R; Comoglio PM; van Dongen GA
    Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1857-67. PubMed ID: 18491091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of volume-based measurements on (11)C-methionine PET in glioma patients.
    Kobayashi K; Hirata K; Yamaguchi S; Manabe O; Terasaka S; Kobayashi H; Shiga T; Hattori N; Tanaka S; Kuge Y; Tamaki N
    Eur J Nucl Med Mol Imaging; 2015 Jun; 42(7):1071-80. PubMed ID: 25852010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer.
    Menke-van der Houven van Oordt CW; Gootjes EC; Huisman MC; Vugts DJ; Roth C; Luik AM; Mulder ER; Schuit RC; Boellaard R; Hoekstra OS; van Dongen GA; Verheul HM
    Oncotarget; 2015 Oct; 6(30):30384-93. PubMed ID: 26309164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased tryptophan uptake on PET has strong independent prognostic value in patients with a previously treated high-grade glioma.
    Kamson DO; Mittal S; Robinette NL; Muzik O; Kupsky WJ; Barger GR; Juhász C
    Neuro Oncol; 2014 Oct; 16(10):1373-83. PubMed ID: 24670609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of PET/CT imaging with [89Zr]Zr-DFO-girentuximab: a phase 1 clinical study in Japanese patients with renal cell carcinoma (Zirdac-JP).
    Nakaigawa N; Hasumi H; Utsunomiya D; Yoshida K; Ishiwata Y; Oka T; Hayward C; Makiyama K
    Jpn J Clin Oncol; 2024 Aug; 54(8):873-879. PubMed ID: 38864246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic mapping of gliomas using hybrid MR-PET imaging: feasibility of the method and spatial distribution of metabolic changes.
    Bisdas S; Ritz R; Bender B; Braun C; Pfannenberg C; Reimold M; Naegele T; Ernemann U
    Invest Radiol; 2013 May; 48(5):295-301. PubMed ID: 23296081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.
    Hutterer M; Nowosielski M; Putzer D; Waitz D; Tinkhauser G; Kostron H; Muigg A; Virgolini IJ; Staffen W; Trinka E; Gotwald T; Jacobs AH; Stockhammer G
    J Nucl Med; 2011 Jun; 52(6):856-64. PubMed ID: 21622893
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.